The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Open accessAbstract
Nanotechnology offers many advantages in various fields of science. In this regard, nanoparticles are the essential building blocks of nanotechnology. Recent advances in nanotechnology have proven that nanoparticles acquire a great potential in medical applications. Formation of stable interactions with ligands, variability in size and shape, high carrier capacity, and convenience of binding of both hydrophilic and hydrophobic substances make nanoparticles favorable platforms for the target-specific and controlled delivery of micro- and macromolecules in disease therapy. Nanoparticles combined with the therapeutic agents overcome problems associated with conventional therapy; however, some issues like side effects and toxicity are still debated and should be well concerned before their utilization in biological systems. It is therefore important to understand the specific properties of therapeutic nanoparticles and their delivery strategies. Here, we provide an overview on the unique features of nanoparticles in the biological systems. We emphasize on the type of clinically used nanoparticles and their specificity for therapeutic applications, as well as on their current delivery strategies for specific diseases such as cancer, infectious, autoimmune, cardiovascular, neurodegenerative, ocular, and pulmonary diseases. Understanding of the characteristics of nanoparticles and their interactions with the biological environment will enable us to establish novel strategies for the treatment, prevention, and diagnosis in many diseases, particularly untreatable ones.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helical microtubules of graphitic carbon
Iijima, S. (1991) · Nature · doi:10.1038/354056a0 · Cited by 43,098
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“For the efficient targeted delivery, the agent-loaded system should be retained in the physiological system for the preferable time, evade the immunological system, target specific cell/tissue, and release the loaded therapeutic agent [91].”
BackgroundThe antimicrobial activity of nanoparticles: present situation and prospects for the future
Wang, L., Hu, C., & Shao, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s121956 · Cited by 4,062
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Cited by
Drug release study of the chitosan-based nanoparticles
Herdiana, Y., Wathoni, N., Shamsuddin, S., & Muchtaridi, M. (2022) · Heliyon · doi:10.1016/j.heliyon.2021.e08674 · Cited by 576
“The administration of NPs depends on the target location [48, 49, 50].”
BackgroundAdvances in nanomaterial-based targeted drug delivery systems
Cheng, X., Xie, Q., & Sun, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1177151 · Cited by 395
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Gold nanoparticles and gold nanorods in the landscape of cancer therapy
Kesharwani, P., Ma, R., Sang, L., Fatima, M., Sheikh, A., Abourehab, M. A. S., Gupta, N., Chen, Z.-S., & Zhou, Y. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01798-8 · Cited by 337
Hetta, H. F., Ramadan, Y. N., Al-Harbi, A. I., A. Ahmed, E., Battah, B., Abd Ellah, N. H., Zanetti, S., & Donadu, M. G. (2023) · Biomedicines · doi:10.3390/biomedicines11020413 · Cited by 333
Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review
Al-Thani, A. N., Jan, A. G., Abbas, M., Geetha, M., & Sadasivuni, K. K. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122899 · Cited by 323
Mba, I. E., & Nweze, E. I. (2021) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-021-03070-x · Cited by 321
Nanoparticles in Clinical Translation for Cancer Therapy
Mundekkad, D., & Cho, W. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 305
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Li, S., Chen, L., & Fu, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01992-2 · Cited by 277
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Niosomal drug delivery systems for ocular disease-recent advances and future prospects
Durak, S., Esmaeili Rad, M., Alp Yetisgin, A., Eda Sutova, H., Kutlu, O., Cetinel, S., & Zarrabi, A. (2020) · Nanomaterials · doi:10.3390/nano10061191 · Cited by 196
Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment
Herdiana, Y., Wathoni, N., Shamsuddin, S., Joni, I. M., & Muchtaridi, M. (2021) · Polymers · doi:10.3390/polym13111717 · Cited by 196
Kim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y. (2024) · Small Science · doi:10.1002/smsc.202400280 · Cited by 97
Aram, E., Moeni, M., Abedizadeh, R., Sabour, D., Sadeghi-Abandansari, H., Gardy, J., & Hassanpour, A. (2022) · Nanomaterials · doi:10.3390/nano12203567 · Cited by 66
Apolipoproteins: New players in cancers
He, Y., Chen, J., Ma, Y., & Chen, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1051280 · Cited by 52
Cybulski, P., Bravo, M., Chen, J. J.-K., Van Zundert, I., Krzyzowska, S., Taemaitree, F., Uji-i, H., Hofkens, J., Rocha, S., & Fortuni, B. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1520078 · Cited by 51
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Modulating active targeting nanoparticle design according to tumor progressions
Nie, H., Huang, R., Jiang, G., Li, W., Yang, L., Zhang, M., Qian, M., Guo, W., Ye, T., & Huang, R. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.016 · Cited by 15
Metadata
- Authors
- Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-05-08
- Volume
- 25
- Issue
- 9
- Pages
- 2193
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3021977647
- Cited by
- 1,080
- References
- 240
- FWCI
- 23.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.